Squarepoint Ops LLC Invests $3.70 Million in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Squarepoint Ops LLC acquired a new position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 87,989 shares of the biopharmaceutical company's stock, valued at approximately $3,702,000. Squarepoint Ops LLC owned 0.10% of Ultragenyx Pharmaceutical at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in Ultragenyx Pharmaceutical by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 10,034,862 shares of the biopharmaceutical company's stock worth $422,167,000 after purchasing an additional 89,389 shares during the period. Invesco Ltd. raised its position in shares of Ultragenyx Pharmaceutical by 1.5% in the 4th quarter. Invesco Ltd. now owns 1,699,756 shares of the biopharmaceutical company's stock worth $71,509,000 after buying an additional 25,487 shares during the period. Alliancebernstein L.P. raised its position in shares of Ultragenyx Pharmaceutical by 5.3% in the 4th quarter. Alliancebernstein L.P. now owns 1,627,932 shares of the biopharmaceutical company's stock worth $68,487,000 after buying an additional 81,667 shares during the period. Alyeska Investment Group L.P. raised its position in shares of Ultragenyx Pharmaceutical by 23.1% in the 4th quarter. Alyeska Investment Group L.P. now owns 1,439,740 shares of the biopharmaceutical company's stock worth $60,570,000 after buying an additional 269,733 shares during the period. Finally, Point72 Asset Management L.P. raised its holdings in shares of Ultragenyx Pharmaceutical by 81.0% in the 4th quarter. Point72 Asset Management L.P. now owns 1,182,877 shares of the biopharmaceutical company's stock worth $49,764,000 after purchasing an additional 529,217 shares during the period. Hedge funds and other institutional investors own 97.67% of the company's stock.

Analyst Upgrades and Downgrades

RARE has been the topic of a number of research reports. Morgan Stanley raised their price objective on Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. JPMorgan Chase & Co. raised their price target on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Cantor Fitzgerald reissued an "overweight" rating and issued a $118.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 26th. HC Wainwright reissued a "buy" rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. Finally, Canaccord Genuity Group raised their target price on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a research note on Tuesday, February 18th. One research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $89.31.

Ultragenyx Pharmaceutical Stock Performance

Shares of NASDAQ RARE traded up $0.68 during midday trading on Thursday, reaching $35.03. 1,217,626 shares of the company's stock were exchanged, compared to its average volume of 836,484. Ultragenyx Pharmaceutical Inc. has a 52-week low of $29.59 and a 52-week high of $60.37. The stock has a market capitalization of $3.31 billion, a PE ratio of -5.53 and a beta of 0.34. The business's fifty day moving average price is $35.80 and its two-hundred day moving average price is $40.92.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.03). The business had revenue of $139.29 million for the quarter, compared to analysts' expectations of $145.98 million. Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. Ultragenyx Pharmaceutical's revenue for the quarter was up 28.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($2.03) earnings per share. Analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Thomas Richard Kassberg sold 6,028 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total value of $253,778.80. Following the sale, the executive vice president now directly owns 265,238 shares in the company, valued at $11,166,519.80. This trade represents a 2.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Theodore Alan Huizenga sold 967 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $40,710.70. Following the completion of the sale, the chief accounting officer now owns 50,265 shares in the company, valued at approximately $2,116,156.50. This represents a 1.89% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 122,415 shares of company stock valued at $5,156,958 over the last three months. Company insiders own 5.50% of the company's stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.